Market Overview

XTL Biopharma Buys Stake in Proteologics from Teva

Related TEVA
Teva Announces UK High Court Gives Positive Judgment In The Company's Patent Case Against AstraZeneca
Notable Hedge Funds Disclose Additions And Reductions To Holdings
Sofinnova Ventures Closes $500M Fund (Fox Business)

XTL Biopharmaceuticals Ltd. announced on November 21^st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium). The Shares represent all of Teva's shares in Proteologics and represent approximately 31.35% of Proteologics issued and outstanding share capital.

Posted-In: News Asset Sales

 

Related Articles (TEVA)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters